<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951482</url>
  </required_header>
  <id_info>
    <org_study_id>NSCLC brain metastasis 02</org_study_id>
    <nct_id>NCT01951482</nct_id>
  </id_info>
  <brief_title>Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer</brief_title>
  <official_title>Multicenter Phase II Study of Pemetrexed/Cisplatin With or Without Bevacizumab in Patients With Brain Metastases From Non Squamous Non-small Cell Lung Cancer Harboring EGFR Wild Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase II randomized controlled study to assess the efficacy of
      Pemetrexed/cisplatin with or without Bevacizumab on patients with brain metastasis from
      non-small cell lung cancer(NSCLC) harboring EGFR wild type by intracranial PFS(iPFS),also PFS
      ,DCR and OS.The side effect is evaluated as well.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare iPFS(intracranial progression free survival) in two arms</measure>
    <time_frame>3 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate(CR&amp;PR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>PFS: progress free survival</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>OS: overall survival</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Non Squamous Non-small Cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <condition>Bevacizumab</condition>
  <arm_group>
    <arm_group_label>Bevacizumab and Pemetrexed/cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed/cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed/cisplatin q21d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed/cisplatin</intervention_name>
    <description>receive Pemetrexed/cisplatin every 21 days</description>
    <arm_group_label>Pemetrexed/cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab and Pemetrexed/cisplatin</intervention_name>
    <description>receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days</description>
    <arm_group_label>Bevacizumab and Pemetrexed/cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient who was confirmed stage IV non squamous NSCLC with EGFR wild type and brain
             metastases by pathologic histology or cytology

          2. Patients who had never received therapy (including chemotherapy,WBRT,and Bevacizumab)
             after diagnosed brain metastases

          3. Appraisable disease, the presence of at least three lesions if longest diameter &lt;10 mm
             by brain MRI

          4. Adult patients (≥ 18 years and ≤75 years). ECOG Performance Status 0 or 1 Life
             expectancy of at least 12 weeks.,Haemoglobin ³ 10.0 g/dl, Absolute neutrophil count
             (ANC) ³1.5 x 109/L, platelets ³ 100 x 109/L. Total bilirubin £ 1.5 x upper limit of
             normal (ULN). ALT and AST &lt; 2.5 x ULN in the absence of liver metastases, or &lt; 5 x ULN
             in case of liver metastases. Creatinine clearance ³ 60ml/min (calculated according to
             Cockcroft-gault formula).

          5. Patients should be contraceptive during the period of the trial

        Exclusion Criteria:

          1. Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a
             predominant squamous component.

          2. History of haemoptysis

          3. Evidence of tumour invading major blood vessels on imaging.

          4. Patient was received irradiation of brain. Patient with meningeal metastases were
             confirmed by MRI or cytology test of cerebrospinal fluid.

          5. Previous radiotherapy.

          6. Serious uncontrolled coagulation disorder or thrombi-embolic complications within 6
             months prior to study start or history of serious bleeding complications.

          7. Major surgical procedures within 4 weeks prior to study entry.

          8. Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to
             the first bevacizumab infusion.

          9. Non-healing wound, active peptic ulcer or bone fracture.

         10. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
             within 6 months of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>li-kun Chen, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>li-kun hen, Doctor</last_name>
    <phone>13798019964</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University of Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li-kun Chen, doctor</last_name>
      <phone>13798019964</phone>
      <email>chenlk@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li-kun Chen</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

